187 related articles for article (PubMed ID: 29879177)
1. Treatment patterns and outcomes in patients with metastatic gastric cancer receiving third-line chemotherapy: A population-based outcomes study.
Choi IS; Choi M; Lee JH; Kim JH; Suh KJ; Lee JY; Kang B; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(6):e0198544. PubMed ID: 29879177
[TBL] [Abstract][Full Text] [Related]
2. A population-based outcomes study of patients with metastatic gastric cancer receiving second-line chemotherapy: A nationwide health insurance database study.
Choi IS; Kim JH; Lee JH; Suh KJ; Lee JY; Kim JW; Kim SH; Kim JW; Lee JO; Kim YJ; Bang SM; Lee JS; Lee KW
PLoS One; 2018; 13(10):e0205853. PubMed ID: 30346970
[TBL] [Abstract][Full Text] [Related]
3. 5-fluorouracil, leucovorin, and irinotecan (FOLFIRI) as a third-line chemotherapy treatment in metastatic gastric cancer, after failure of fluoropyrimidine, platinum, anthracycline, and taxane.
Erdem GU; Bozkaya Y; Ozdemir NY; Demirci NS; Yazici O; Zengin N
Bosn J Basic Med Sci; 2018 May; 18(2):170-177. PubMed ID: 28941466
[TBL] [Abstract][Full Text] [Related]
4. Irinotecan combined with 5-fluorouracil and leucovorin third-line chemotherapy after failure of fluoropyrimidine, platinum, and taxane in gastric cancer: treatment outcomes and a prognostic model to predict survival.
Kang EJ; Im SA; Oh DY; Han SW; Kim JS; Choi IS; Kim JW; Kim YJ; Kim JH; Kim TY; Lee JS; Bang YJ; Lee KW
Gastric Cancer; 2013 Oct; 16(4):581-9. PubMed ID: 23266882
[TBL] [Abstract][Full Text] [Related]
5. Salvage chemotherapy with the combination of oxaliplatin, leucovorin, and 5-fluorouracil in advanced gastric cancer refractory or intolerant to fluoropyrimidines, platinum, taxanes, and irinotecan.
Kondoh C; Kadowaki S; Komori A; Narita Y; Taniguchi H; Ura T; Ando M; Muro K
Gastric Cancer; 2018 Nov; 21(6):1050-1057. PubMed ID: 29658055
[TBL] [Abstract][Full Text] [Related]
6. Chemotherapy for advanced gastric cancer.
Wagner AD; Syn NL; Moehler M; Grothe W; Yong WP; Tai BC; Ho J; Unverzagt S
Cochrane Database Syst Rev; 2017 Aug; 8(8):CD004064. PubMed ID: 28850174
[TBL] [Abstract][Full Text] [Related]
7. Third-Line Chemotherapy with Irinotecan plus 5-Fluorouracil in Caucasian Metastatic Gastric Cancer Patients.
Pasquini G; Vasile E; Caparello C; Vivaldi C; Musettini G; Lencioni M; Petrini I; Fornaro L; Falcone A
Oncology; 2016; 91(6):311-316. PubMed ID: 27705972
[TBL] [Abstract][Full Text] [Related]
8. Randomised phase II trial comparing four front-line doublets in Asian patients with metastatic gastric cancer.
Kim C; Chon HJ; Kim JH; Jung M; Nam CM; Kim HS; Kang B; Chung HC; Rha SY
Eur J Cancer; 2019 May; 112():20-28. PubMed ID: 30901609
[TBL] [Abstract][Full Text] [Related]
9. The Clinical and Cost Effectiveness of Aflibercept in Combination with Irinotecan and Fluorouracil-Based Therapy (FOLFIRI) for the Treatment of Metastatic Colorectal Cancer Which has Progressed Following Prior Oxaliplatin-Based Chemotherapy: a Critique of the Evidence.
Wade R; Duarte A; Simmonds M; Rodriguez-Lopez R; Duffy S; Woolacott N; Spackman E
Pharmacoeconomics; 2015 May; 33(5):457-66. PubMed ID: 25616671
[TBL] [Abstract][Full Text] [Related]
10. Three fluoropyrimidine-based regimens in routine clinical practice after nab-paclitaxel plus gemcitabine for metastatic pancreatic cancer: An AGEO multicenter study.
Pointet AL; Tougeron D; Pernot S; Pozet A; Béchade D; Trouilloud I; Lourenco N; Hautefeuille V; Locher C; Williet N; Desrame J; Artru P; Soularue E; Le Roy B; Taieb J
Clin Res Hepatol Gastroenterol; 2020 Jun; 44(3):295-301. PubMed ID: 31607641
[TBL] [Abstract][Full Text] [Related]
11. Second-line irinotecan after cisplatin, fluoropyrimidin and docetaxel for chemotherapy of metastatic gastric cancer.
Kucukzeybek Y; Dirican A; Erten C; Somali I; Can A; Demir L; Bayoglu IV; Akyol M; Medeni M; Tarhan MO
Asian Pac J Cancer Prev; 2012; 13(6):2771-4. PubMed ID: 22938457
[TBL] [Abstract][Full Text] [Related]
12. A phase II study of irinotecan, continuous 5-fluorouracil, and leucovorin (FOLFIRI) combination chemotherapy for patients with recurrent or metastatic gastric cancer previously treated with a fluoropyrimidine-based regimen.
Kim SH; Lee GW; Go SI; Cho SH; Kim HJ; Kim HG; Kang JH
Am J Clin Oncol; 2010 Dec; 33(6):572-6. PubMed ID: 20042971
[TBL] [Abstract][Full Text] [Related]
13. Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial.
Hironaka S; Ueda S; Yasui H; Nishina T; Tsuda M; Tsumura T; Sugimoto N; Shimodaira H; Tokunaga S; Moriwaki T; Esaki T; Nagase M; Fujitani K; Yamaguchi K; Ura T; Hamamoto Y; Morita S; Okamoto I; Boku N; Hyodo I
J Clin Oncol; 2013 Dec; 31(35):4438-44. PubMed ID: 24190112
[TBL] [Abstract][Full Text] [Related]
14. Comparison the efficacy of second-line modified EOX (epirubicin, oxaliplatin, and capecitabine) and irinotecan, 5-fluorouracil, and leucovorin (FOLFIRI) regimens in metastatic gastric cancer patients that progressed on first-line modified docetaxel and cisplatin plus fluorouracil (DCF) regimen.
Sendur MA; Ozdemir N; Özatlı T; Yazıcı O; Aksoy S; Ekinci AS; Yazılıtaş D; Günaydın Y; Oksuzoglu B; Benekli M; Zengin N
Med Oncol; 2014 Sep; 31(9):153. PubMed ID: 25099765
[TBL] [Abstract][Full Text] [Related]
15. Treatment patterns and clinical outcomes in patients with metastatic colorectal cancer initially treated with FOLFOX-bevacizumab or FOLFIRI-bevacizumab: results from ARIES, a bevacizumab observational cohort study.
Bendell JC; Bekaii-Saab TS; Cohn AL; Hurwitz HI; Kozloff M; Tezcan H; Roach N; Mun Y; Fish S; Flick ED; Dalal D; Grothey A
Oncologist; 2012; 17(12):1486-95. PubMed ID: 23015662
[TBL] [Abstract][Full Text] [Related]
16. Sequential chemotherapies for advanced gastric cancer: a retrospective analysis of 111 patients.
Elsing C; Herrmann C; Hannig CV; Stremmel W; Jäger D; Herrmann T
Oncology; 2013; 85(5):262-8. PubMed ID: 24192723
[TBL] [Abstract][Full Text] [Related]
17. Modified FOLFOX-6 therapy for heavily pretreated advanced gastric cancer refractory to fluorouracil, irinotecan, cisplatin and taxanes: a retrospective study.
Tsuji K; Yasui H; Onozawa Y; Boku N; Doyama H; Fukutomi A; Yamazaki K; Machida N; Todaka A; Taniguchi H; Tsushima T; Yokota T
Jpn J Clin Oncol; 2012 Aug; 42(8):686-90. PubMed ID: 22693245
[TBL] [Abstract][Full Text] [Related]
18. [Fifth-line chemotherapy for metastatic gastric cancer--a case responding to modified FOLFOX 6].
Sagawa T; Sato Y; Takayama T; Kuroda H; Hirakawa M; Abe S; Iyama S; Sakamaki S; Kato J; Niitsu Y
Gan To Kagaku Ryoho; 2007 Sep; 34(9):1467-71. PubMed ID: 17876148
[TBL] [Abstract][Full Text] [Related]
19. Docetaxel, Oxaliplatin, and 5-Fluorouracil (DOF) in Metastatic and Unresectable Gastric/Gastroesophageal Junction Adenocarcinoma: A Phase II Study with Long-Term Follow-Up.
Rosenberg AJ; Rademaker A; Hochster HS; Ryan T; Hensing T; Shankaran V; Baddi L; Mahalingam D; Mulcahy MF; Benson AB
Oncologist; 2019 Aug; 24(8):1039-e642. PubMed ID: 31138725
[TBL] [Abstract][Full Text] [Related]
20. [Oxaliplatin and leucovorin plus fluorouracil versus irinotecan and leucovorin plus fluorouracil combination chemotherapy as a first-line treatment in patients with metastatic or recurred gastric adenocarcinoma].
Kang SH; Kim JI; Moon HS; Kim SH; Sung JK; Lee BS; Jeong HY
Korean J Gastroenterol; 2010 Jan; 55(1):26-32. PubMed ID: 20098064
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
